Precision BioSciences raised $25.6M

What does Precision BioSciences?

Precision Biosciences, is a biotechnology company whose mission is to translate the world’s most powerful genome editing technology into greatly required products throughout the life sciences. Its patent ARCUS genome editing technology enables the production of nucleases which can insert, remove and modify DNA at essentially any location of a complex genome.

ARCUS technology is a combo of flexibility and precision.

How much Precision BioSciences was funded?

Precision Biosciences raised $25.6M in Series A funding on May 11^th, 2015 from venBio, Osage University Partners, Ziegler-LinkAge Longevity Fund, Amgen Ventures, Baxter Ventures and Fidelity Biosciences.

What is next for Precision Biosciences?

Precision Biosciences will join Precision Board. He said he is excited to join the team and help the company achieve its goals. The latest funding will be used to accelerate the development of greatly necessary products which are enabled by the ARCUS genome editing technology.

The financing will allow the company to expand beyond its successful efforts in developing the leading next generation genome editing platform and to significantly accelerate the development of its genome edited pipeline.

More about Precision Biosciences

Precision Biosciences has its headquarters in Durham, NC. Its aim is to translate the world’s most powerful genome editing technology into greatly necessary products through life sciences. Its ARCUS genome editing technology enables producing highly specific nucleases which can remove or insert or modify DNA at any location in genome. Its vision is to be conduit through which the greatest genome engineering challenges are solved. It is developing genome editing based product which addresses important needs in agriculture, health and a lot more.

It focuses on developing greatly necessary products which are enabled by the ARCUS genome editing technology. This company’s mission is translating the world’s most powerful genome editing technology into products throughout the life sciences.